ArticleCancer causes & control : CCC2025
Evaluating Now I Know mHealth intervention promoting HPV vaccine completion among young women attending federally supported clinics.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the feasibility, acceptability, usability, and HPV vaccine completion rate of the Now I Know (NIK) mHealth intervention to promote HPV vaccine completion among minority and low-income young women.
methodsThis quasi-experimental pilot study recruited 35 women aged 18-26 at two federally supported outpatient clinics in a large city in the Northeastern United States. Participants were allocated to two groups: 24 received the NIK intervention plus usual care and 11 received usual care only. After completing a baseline assessment, intervention group participants launched the NIK mobile app, which entailed HPV vaccine education, self-managed vaccine record & reminder, and Q&A features. Follow-up visits were conducted at 2 and 6 months. Feasibility was assessed through screening, recruitment, fidelity, and retention. Acceptability and usability were evaluated via survey and exit interview. The primary outcome-HPV vaccine 3-dose series completion-was analyzed using descriptive statistics.
resultsThis study demonstrated feasibility by reaching the recruitment target (n = 35) and high retention rate (89%). Participants reported the app was acceptable, appreciating reliable information, convenient access, providing a personal touch, and raising awareness. Regarding usability, users found the app easy to navigate, accessible, well organized, and user-friendly. The HPV vaccine completion rate was higher in the intervention group (55%) than in the usual care group (45.5%).
conclusionFindings showed improved vaccination completion among those using the Now I Know mHealth intervention (compared to usual care), acceptability of the intervention, and feasibility of recruiting, retaining, and delivering the intervention to promote HPV vaccine completion among young women in federally subsidized healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.